A substantial burden of hospitalizations for PIV-associated ARI was observed among pediatric patients in the United States.

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

Maternal vaccination and, to a lesser extent, nirsevimab appear to significantly reduce RSV-related hospitalizations in infants.

Patients with RSV hospitalization have increased odds of any acute cardiovascular event compared with COVID-19 hospitalizations.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

In response to the global burden of severe respiratory syncytial virus (RSV) disease among infants, the World Health ...

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...